In 1442 infants aged 6–8 weeks in Bangladesh and Pakistan, Sabin inactivated polio vaccine (sIPV) given with routine vaccines gave seroconversion of 90.3%, 91.7% and 86.4% (types I–III) vs 87.0%, 91.3% and 92.3% when staggered; adverse reactions 92.8% vs 95.5%.
RCTn = 1,442
Islam et al. A multi-center, open-labelled, randomized controlled extended phase III non-inferiority clinical trial to evaluate the immunogenicity and tolerability of poliomyelitis vaccine (Vero cells), inactivated, Sabin strains administered with or without routine infant vaccines